- Home
- Companies
- uzbekistan
- disease ibd
Show results for
Refine by
Disease Ibd Suppliers Serving Uzbekistan
9 companies found
based inShanghai, CHINA
Focusing on the core raw materials of the life science industry, Yeasen Biotechnology (Shanghai) Co., Ltd. is a biotechnology company engaged in the research and development, production and sales of three major categories of biological reagents: ...
Dextran sulfate sodium salt (DSS) is a polyanionic derivative of dextran produced by esterification of Dextran with chlorosulphonic acid. The sulfur content is approximately 17% which corresponds to an average of 1.9 sulfate groups per glucosyl ...
based inBoca Raton, FLORIDA (USA)
Entero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. At the core of its research are three proprietary technologies. Latiglutenase is an ...
based inMapo, SOUTH KOREA
MD Healthcare contributes to being healthy through innovative healthcare solutions based on cutting edge science and technology. One of the most revolutionary advances in the biological sciences in recent years has been the realization that ...
based inAsheville,, NORTH CAROLINA (USA)
Headquartered in Asheville, N.C., Genova Diagnostics is a global specialty clinical laboratory, pioneering a systems approach that supports healthcare providers in the personalized treatment and prevention of chronic disease. Chronic diseases are ...
A Non-Invasive Stool Biomarker of Pancreatic Exocrine Function. Pancreatic elastase is a protein-digesting enzyme exclusively produced by the human pancreas, and serves as a non-invasive stool biomarker of pancreatic exocrine function. Pancreatic ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, ...
based inSan Diego, CA 92126 USA, CALIFORNIA (USA)
America Diagnostics, Inc. is a California company that develops and produces IVD devices and diagnostics raw materials. The quality of AmeriDx products is guaranteed by its quality management system. All the products are manufactured in a clean ...
The AmeriDx® Calprotectin (CPTN) Rapid Test Kit is a qualitative test that detects CPTN antigen in human fecal specimens and other body ...
based inBuk-gu, SOUTH KOREA
JD Bioscience (JDB) is a group of experts in small molecule-based novel drug development. JD Bioscience was established by a team of highly experienced medicinal chemists, biologists, and clinicians in the field of endocrine and metabolic diseases. ...
IBD, including ulcerative colitis (UC) and crohn’s disease (CD) can be caused by genetic and environmental factors and can induces uncontrolled activation of intestinal immune cells. Pro-inflammatory ...
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), ...